Psychedelics, such as ketamine, MDMA, psilocybin, and LSD have been tightly controlled and highly debated substances for decades, but after several years of clinical trials, the FDA has recently awarded both MDMA and psilocybin, when used in conjunction with psychotherapy, with breakthrough status for the research of challenging mental health disorders, like PTSD. The breakthrough status designation means that the FDA will expedite the review of the research. Mental health advocates are keen to open these treatments to a wider demographic of patients. And, it’s important to note that there’s been a long tradition of psychedelic use as a healing practice among cultures across the world. So, is modern society ready to embrace psychedelics? Newly passed local laws show that it’s becoming more widely accepted. Legal access to psilocybin is already available in parts of the US and Canada. Joining us on this episode is Ronan Levy, co-founder and Executive Chairman of Field Trip Psychedelics a new company that is treating patients who have mental health diagnoses with ketamine-assisted psychotherapy. Together, Dr. Weil, Dr. Maizes, and Levy discuss important aspects of psychedelic treatment. Dr. Weil defines psychedelic-assisted therapy and how it works. Dr. Maizes raises the questions, “What should be considered when applying these treatments?” and “When will it be made available to patients?” Levy describes the current regulations and laws around the substances in the US and Canada, the treatment protocols at his clinic, and what the future holds for patients seeking psychedelic-assisted therapy.

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Transcript

Related